2-5 November 2020
Melia Sitges Hotel Resort, Barcelona, Spain
➤ Defining the value of orphan drugs from societal impact to pricing models
➤ Pre-approval access, a key component of your strategic rare disease drug development
➤ RWE models supporting patient access to new therapies
➤ What is the relationship between price and prevalence in rare diseases?
➤ The framework for conducting and tracking commercial negotiations in HTA
➤ Cross-country collaboration on evidence generation from Beneluxa, V4+, Nordics and the Valetta declaration